Decoding Haematological Toxicity Associated with Antibody-Drug Conjugates: Mechanisms, Clinical Profiles and Management Strategies

Authors

  • Samarth R. Rathod ORCiD Department of Pharmacy Practice, Sharda School of Pharmacy, Pethapur, Gandhinagar, Gujarat, India
  • Amar M. Raval ORCiD Department of Pharmaceutics, Sharda School of Pharmacy, Pethapur, Gandhinagar, Gujarat, India
  • Aastha Ukani ORCiD Department of Pharmacy Practice, Sharda School of Pharmacy, Pethapur, Gandhinagar, Gujarat, India
  • Jaini Patel ORCiD Department of Pharmaceutics, Sharda School of Pharmacy, Pethapur, Gandhinagar, Gujarat, India
  • Ashok Kumar ORCiD Department of Pharmacy Practice, Sharda School of Pharmacy, Pethapur, Gandhinagar, Gujarat, India

DOI:

https://doi.org/10.68163/ptr.2026.76

Keywords:

Anaemia, antibody-drug conjugates, dose modification, hematologic toxicity, linker, neutropenia, payload, thrombocytopenia

Abstract

Antibody-drug conjugates (ADCs) improve targeted drug delivery but are often associated with hematological toxicity. This review examines the structural, mechanistic and clinical evidence on ADC-induced hematological toxicity, focusing on approved ADCs and strategies for dose adjustment. Approved ADCs, including Gemtuzumab Ozogamicin (GO), Inotuzumab Ozogamicin (IO), trastuzumab emtansine, brentuximab vedotin, Polatuzumab Vedotin (PV), Sacituzumab Govitecan (SG), trastuzumab deruxtecan, Enfortumab Vedotin (EV), tisotumab vedotin, Loncastuximab Tesirine (LT), belantamab mafodotin, mirvetuximab soravtansine and disitamab vedotin, exhibit distinct hematological toxicity profiles. Common adverse events include neutropenia, thrombocytopenia, anemia, leukopenia, lymphopenia and febrile neutropenia. These toxicities are influenced by factors such as antigen distribution, linker stability, payload characteristics, drug-to-antibody ratio, Fc receptor-mediated uptake and nonspecific endocytosis. Management strategies include dose interruption or reduction, growth factor support, transfusions and regular laboratory monitoring. Hematological toxicity is an important factor affecting the tolerability of ADCs. Understanding the mechanisms underlying these toxicities is essential for improving their clinical management and guiding the development of safer next-generation ADCs.

Downloads

Download data is not yet available.

References

Wang R, Hu B, Pan Z, et al. Antibody-drug conjugates (ADCs): current and future biopharmaceuticals. J Hematol Oncol. 2025;18(1):51. doi:10.1186/s13045-025-01704-3 DOI: https://doi.org/10.1186/s13045-025-01704-3

Ballestín P, López de Sá A, Díaz-Tejeiro C, et al. Understanding the toxicity profile of approved ADCs. Pharmaceutics. 2025;17(2):258. doi:10.3390/pharmaceutics17020258 DOI: https://doi.org/10.3390/pharmaceutics17020258

Chis AA, Dobrea CM, Arseniu AM, et al. Antibody-drug conjugates: evolution and perspectives. Int J Mol Sci. 2024;25(13):6969. doi:10.3390/ijms25136969 DOI: https://doi.org/10.3390/ijms25136969

Metrangolo V, Engelholm LH. Antibody-drug conjugates: the dynamic evolution from conventional to next-generation constructs. Cancers. 2024;16(2):447. doi:10.3390/cancers16020447 DOI: https://doi.org/10.3390/cancers16020447

He J, Zeng X, Wang C, Wang E, Li Y. Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies. MedComm. 2024;5(8):e671. doi:10.1002/mco2.671 DOI: https://doi.org/10.1002/mco2.671

Colombo R, Tarantino P, Rich JR, LoRusso PM, de Vries EGE. The journey of antibody-drug conjugates: lessons learned from 40 years of development. Cancer Discov. 2024;14(11):2089-2108. DOI: https://doi.org/10.1158/2159-8290.CD-24-0708

Cheng Y, Lu J, Zhang C, et al. Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors. Antib Ther. 2025;8(2):124-144. DOI: https://doi.org/10.1093/abt/tbaf004

Rao M, Wu L, Chen H, et al. Haematological toxicity of anti-tumour antibody-drug conjugates: A retrospective pharmacovigilance study using the FDA adverse event reporting system. PLoS One. 2025;20(10):e0334513. doi:10.1371/journal.pone.0334513 DOI: https://doi.org/10.1371/journal.pone.0334513

Tan HN, Morcillo MA, Lopez J, et al. Treatment-related adverse events of antibody drug-conjugates in clinical trials. J Hematol Oncol. 2025;18(1):71. doi:10.1186/s13045-025-01720-3 DOI: https://doi.org/10.1186/s13045-025-01720-3

Masters JC, Nickens DJ, Xuan D, Shazer RL, Amantea M. Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads. Invest New Drugs. 2018;36(1):121-135. DOI: https://doi.org/10.1007/s10637-017-0520-6

Montalbano MC, Micillo M, Deaglio S, Vaisitti T. Antibody-drug conjugates in haematological malignancies: current landscape and future perspectives. Int J Mol Sci. 2026;27(2):1025. doi:10.3390/ijms27021025 DOI: https://doi.org/10.3390/ijms27021025

Tang SC, Wynn C, Le T, et al. Influence of antibody-drug conjugate cleavability, drug-to-antibody ratio, and free payload concentration on systemic toxicities: a systematic review and meta-analysis. Cancer Metastasis Rev. 2025;44(1):18. doi:10.1007/s10555-024-10231-5 DOI: https://doi.org/10.1007/s10555-024-10231-5

Liu X, Yin S, Li X, Nie J. Focusing on toxicity management: challenges and strategies for HER2-targeted antibody-drug conjugates in breast cancer. Breast. 2026;86:104741. doi:10.1016/j.breast.2026.104741 DOI: https://doi.org/10.1016/j.breast.2026.104741

Masoud I, Al Shaer NSH, Masoud A, et al. Antibody-drug conjugates in solid tumour oncology and the frontier of precision immunosuppression: a mechanistic, translational, and clinical review. Int J Mol Sci. 2026;27(12):5196. doi:10.3390/ijms27125196 DOI: https://doi.org/10.3390/ijms27125196

Dudchak R, Podolak M, Holota S, et al. Click chemistry in the synthesis of antibody-drug conjugates. Bioorg Chem. 2024;143:106982. doi:10.1016/j.bioorg.2023.106982 DOI: https://doi.org/10.1016/j.bioorg.2023.106982

Beyar-Katz O, Rejeski K, Shouval R. Immune effector cell-associated hematotoxicity: mechanisms, clinical manifestations, and management strategies. Haematologica. Published online February 20, 2025. doi:10.3324/haematol.2024.286027 DOI: https://doi.org/10.3324/haematol.2024.286027

Han X, Xu J, Cui M, et al. Haematological toxicities with immune checkpoint inhibitors in digestive system tumours: A systematic review and network meta-analysis of randomised controlled trials. Clin Exp Med. 2025;25(1):157. doi:10.1007/s10238-025-01688-x DOI: https://doi.org/10.1007/s10238-025-01688-x

Di Leone A, Filippone A, Maggiore C, et al. The role of body composition in neurological and hematologic toxicity in a retrospective analysis of 120 breast cancer patients undergoing neoadjuvant chemotherapy: The COMBOTOX study. Breast Cancer Res Treat. 2025;210(1):205-213. DOI: https://doi.org/10.1007/s10549-024-07553-x

Medina Pérez VM, Baselga M, Schuhmacher AJ. Single-domain antibodies as antibody-drug conjugates: from promise to practice, a systematic review. Cancers. 2024;16(15):2681. doi:10.3390/cancers16152681 DOI: https://doi.org/10.3390/cancers16152681

Bangolo A, Amoozgar B, Mansour C, et al. Comprehensive review of early and late toxicities in CAR T-cell therapy and bispecific antibody treatments for hematologic malignancies. Cancers. 2025;17(2):282. doi:10.3390/cancers17020282 DOI: https://doi.org/10.3390/cancers17020282

Taylor RP, Lindorfer MA. Antibody-drug conjugate adverse effects can be understood and addressed based on immune complex clearance mechanisms. Blood. 2024;144(2):137-144. DOI: https://doi.org/10.1182/blood.2024024442

Jain MD, Abramson JS, Ansell SM. Easy as ABC: managing toxicities of antibody-drug conjugates, bispecific antibodies, and CAR T-cell therapies. Am Soc Clin Oncol Educ Book. 2025;45(3):e473916. doi:10.1200/EDBK-25-473916 DOI: https://doi.org/10.1200/EDBK-25-473916

Kang S, Kim SB. Toxicities and management strategies of emerging antibody-drug conjugates in breast cancer. Ther Adv Med Oncol. 2025;17:17588359251324889. doi:10.1177/17588359251324889 DOI: https://doi.org/10.1177/17588359251324889

Shah AC, Saluja SG, Trivedi JD, et al. Navigating the landscape of antibody drug conjugates: current trends and future research prospects in acute myeloid leukaemia. Front Biosci. 2026;18(1):39323. doi:10.31083/FBE39323 DOI: https://doi.org/10.31083/FBE39323

Zhou K, Liu X, Zhu H. Overcoming resistance to antibody-drug conjugates: From mechanistic insights to cutting-edge strategies. J Hematol Oncol. 2025;18(1):96. doi:10.1186/s13045-025-01752-9 DOI: https://doi.org/10.1186/s13045-025-01752-9

Alradwan IA, Alnefaie MK, Al Fayez N, et al. Strategic and chemical advances in antibody-drug conjugates. Pharmaceutics. 2025;17(9):1164. doi:10.3390/pharmaceutics17091164 DOI: https://doi.org/10.3390/pharmaceutics17091164

Chen B, Zheng X, Wu J, et al. Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions. Mol Cancer. 2025;24(1):279. doi:10.1186/s12943-025-02489-2 DOI: https://doi.org/10.1186/s12943-025-02489-2

Kumari S, Cool LM, Howard E, Pawar JS. Advances and future directions in antibody-drug conjugates: From paradigm shifts to data-driven design. Cancers. 2026;18(13):2102. doi:10.3390/cancers18132102 DOI: https://doi.org/10.3390/cancers18132102

Augusto A, Cristiano MLS, Conceição J. Antibody-drug conjugates: Pharmacotherapeutic properties and future perspectives. Pharmaceutics. 2026;18(4):468. doi:10.3390/pharmaceutics18040468 DOI: https://doi.org/10.3390/pharmaceutics18040468

Ye A. Research advances in antibody-drug conjugates for cancer therapy. Core Press for Sciences; 2026. doi:10.26914/c.cnkihy.2026.007641

Pfizer Inc. MYLOTARG (gemtuzumab ozogamicin) for injection, for intravenous use. Prescribing information. US Food and Drug Administration. Updated September 2017. Accessed November 13, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761060lbl.pdf

Seattle Genetics, Inc. ADCETRIS (brentuximab vedotin) for injection, for intravenous use. Prescribing information. US Food and Drug Administration. August 2011. Accessed November 13, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125388s000%2C125399s000lbl.pdf

Genentech, Inc. KADCYLA (ado-trastuzumab emtansine) for injection, for intravenous use. Prescribing information. US Food and Drug Administration. Updated August 2013. Accessed November 13, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125427s012lbl.pdf

Pfizer Inc. BESPONSA (inotuzumab ozogamicin) for injection, for intravenous use. Prescribing information. US Food and Drug Administration. Updated August 2017. Accessed November 13, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761040Orig1s000LBL.pdf

Genentech, Inc. POLIVY (polatuzumab vedotin-piiq) for injection, for intravenous use. Prescribing information. US Food and Drug Administration. Updated June 2019. Accessed November 13, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf

Approval package for: ENHERTU (fam-trastuzumab deruxtecan-nxki). Center for Drug Evaluation and Research, US Food and Drug Administration. Application No. 761139Orig1s000. December 20, 2019. Accessed November 13, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761139Orig1s000Approv.pdf

Astellas Pharma US, Inc., Seattle Genetics, Inc. PADCEV (enfortumab vedotin-ejfv) for injection, for intravenous use. Prescribing information. US Food and Drug Administration. Updated December 2019. Accessed November 13, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf

Immunomedics, Inc. TRODELVY (sacituzumab govitecan-hziy) for injection, for intravenous use. Prescribing information. US Food and Drug Administration. Updated April 2020. Accessed November 13, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761115s000lbl.pdf

GlaxoSmithKline Intellectual Property Development Ltd. BLENREP (belantamab mafodotin-blmf) for injection, for intravenous use. Prescribing information. US Food and Drug Administration. Updated August 2020. Accessed November 13, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761158s000lbl.pdf

Seagen Inc., Genmab US, Inc. TIVDAK (tisotumab vedotin-tftv) for injection, for intravenous use. Prescribing information. US Food and Drug Administration. Updated September 2021. Accessed November 13, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761208Orig1s000lbl.pdf

Inside information: business updates. RemeGen Co., Ltd. December 3, 2021. Accessed November 13, 2026. https://www.remegen.cn/uploadfile/2022/04/16/202204160859576873.pdf

ADC Therapeutics SA. ZYNLONTA (loncastuximab tesirine-lpyl) for injection, for intravenous use. Prescribing information. US Food and Drug Administration. Updated April 2021. Accessed November 13, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761196s000lbl.pdf

New drug therapy approvals 2022: advancing health through innovation. Center for Drug Evaluation and Research, US Food and Drug Administration. January 2023. Accessed November 13, 2026. https://www.fda.gov/drugs/novel-drug-approvals-fda/new-drug-therapy-approvals-2022

Downloads

Published

2026-11-13

Issue

Section

Review

How to Cite

1.
Rathod SR, Raval AM, Ukani A, Patel J, Kumar A. Decoding Haematological Toxicity Associated with Antibody-Drug Conjugates: Mechanisms, Clinical Profiles and Management Strategies. Pharmacol. Toxicol. Res. [Internet]. 2026 Nov. 13 [cited 2026 Nov. 17];2:85–97. Available from: https://acadpub.com/ptr/article/view/antibody-drug-conjugates-haematological-toxicity-mechanisms-clinical-profiles-management-strategies

Most read articles by the same author(s)

Similar Articles

You may also start an advanced similarity search for this article.